Viridian Therapeutics VRDN Stock Key Catalysts Ahead Q4 2025 Profit Surprises JPMC J P Morgan reaffirms consistent preferred share payout commitments for the next four fiscal quarters Federal Reserve Chair Nomination Confirmation Status Analysis Is Context Therapeutics CNTX stock a good candidate for diversification Q4 2025 EPS Misses Estimates